End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

BACKGROUND: Previous analyses from a randomised trial in women aged 24–45 years have shown the quadrivalent human papillomavirus (qHPV) vaccine to be efficacious in the prevention of infection, cervical intraepithelial neoplasia (CIN), and external genital lesions (EGLs) related to HPV 6/11/16/18. I...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Castellsagué, X, Muñoz, N, Pitisuttithum, P, Ferris, D, Monsonego, J, Ault, K, Luna, J, Myers, E, Mallary, S, Bautista, O M, Bryan, J, Vuocolo, S, Haupt, R M, Saah, A
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2011
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3137403/
https://ncbi.nlm.nih.gov/pubmed/21629249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.185
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller